CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Authors: Yelena Y. Janjigian, Kohei Shitara, Elena Elimova, Jun Zhang, Ming-Huang Chen, Elizabeth Catherine Smyth, Jeeyun Lee, Rui Miao, Silver Liu, Marielle Holmblad, Rui-Hua Xu

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.tps507

Source: Full article

---

Abstract

TPS507